Effects of the sodium‐glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptanKen Ohara, Daisuke Nagata, Takahiro Masuda et al.|Nephrology|2018Cited by 82
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the ratTakahiro Masuda, Daisuke Nagata, Minami Watanabe et al.|American Journal of Physiology-Renal Physiology|2018Cited by 61
Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume RetentionToshimi Imai, Daisuke Nagata, Tetsu Akimoto et al.|Drug Target Insights|2015Cited by 11
Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of FallotKen Ohara, Daisuke Nagata, Tetsu Akimoto et al.|Clinical Medicine Insights Case Reports|2015Cited by 9
Performing Anticoagulation: A Puzzling Case of Cholesterol Embolization SyndromeYusuke Igarashi, Daisuke Nagata, Tetsu Akimoto et al.|Clinical Medicine Insights Case Reports|2017Cited by 9